T1 / Developer announcement
TRG035 exploratory Phase IIa clinical-trial notification announcement
Toregem BioPharma
Page read. Checked 2026-09-17.
Announcement of a regulatory step, not trial results or marketing approval.
Sources
Studies, health guidance and other publications cited in our articles.
T2 / Developer technology description
Our technology
Toregem BioPharma
Page read. Checked 2026-09-17.
Company description and development aims; not independent clinical evidence.
H1 / Regulator decision
OTARMENI accelerated-approval letter
US Food and Drug Administration
FDA approval-letter PDF read; first two pages visually inspected. Checked 2026-09-17.
US indication only. Approval does not establish availability, reimbursement, or appropriateness for a particular person.
H2 / Government patient education
Cochlear implants
NIH / NIDCD
Page read. Checked 2026-09-17.
H3 / Government patient education
Hearing aids
NIH / NIDCD
Page read. Checked 2026-09-17.
B1 / Primary research
A streaming brain-to-voice neuroprosthesis to restore naturalistic communication
Littlejohn, Cho and colleagues / Nature Neuroscience
Abstract and publisher metadata read; full article not accessible. Checked 2026-09-17.
One participant. 80-ms decoding increments are not total end-to-end latency.
S1 / Manufacturer product and indication page
Hand strength and sensation: ARC-EX
ONWARD Medical
Page read. Checked 2026-09-17.
Manufacturer source. Current indication and product description read; pivotal paper could not be fetched, so efficacy percentages are not independently summarized.
D1 / Primary research
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes
Reichman and colleagues / New England Journal of Medicine
Full paper PDF read; abstract and detailed safety page visually inspected. Checked 2026-09-17.
Updated June 23, 2025; small, interim, nonprespecified analysis. Historical result, not a complete September 2026 program update.
D2 / Developer pipeline page
Type 1 diabetes research pipeline
Vertex
Page read. Checked 2026-09-17.
Company source. Does not provide an independent comparative assessment.
D3 / Government patient education
Pancreatic islet transplantation
NIH / NIDDK
Page read. Checked 2026-09-17.
General donor-islet context; do not transfer all donor-islet outcome rates to stem-cell-derived products.
C1 / Primary research
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Rojas and colleagues / Nature; Weill Cornell institutional abstract
Institutional abstract read. Checked 2026-09-17.
DOI 10.1038/s41586-023-06063-y. Historical Phase I study; not a current complete pipeline review.
C2 / Government patient education
Cancer treatment vaccines
NIH / National Cancer Institute
Page read. Checked 2026-09-17.
C3 / Government patient education
HPV and cancer
NIH / National Cancer Institute
Page read. Checked 2026-09-17.
R1 / Government regulatory education
Step 3: Clinical research
US Food and Drug Administration
Page read. Checked 2026-09-17.
R2 / Government regulatory education
Accelerated approval
US Food and Drug Administration
Page read. Checked 2026-09-17.
R3 / Government regulatory education
Breakthrough therapy
US Food and Drug Administration
Page read. Checked 2026-09-17.
G1 / Official publishing guidance
Creating helpful, reliable, people-first content
Google Search Central
Page read. Checked 2026-09-17.
G2 / Official publishing policy
Spam policies for Google web search
Google Search Central
Page read. Checked 2026-09-17.
G3 / Official publishing guidance
Discover and your website
Google Search Central
Page read. Checked 2026-09-17.
G4 / Official platform requirements
Eligibility requirements for AdSense
Google AdSense
Official publisher-help page read in the v3 source check. Checked 2026-09-17.
Eligibility criteria are not a guarantee of acceptance, ad fill, page RPM or revenue.
G5 / Official platform requirements
Consent management requirements for serving ads in the EEA, UK and Switzerland
Google AdSense
Page read. Checked 2026-09-17.
M1 / Official monetization requirements
Mediavine and Journey requirements
Mediavine
Page read. Checked 2026-09-17.
Checked September 17, 2026; eligibility is not acceptance or a revenue forecast.
M2 / Official monetization requirements
Who is eligible for Raptive?
Raptive
Page read. Checked 2026-09-17.
Checked September 17, 2026; traffic geography and domain age requirements apply.
M3 / Government business guidance
Native advertising: a guide for businesses
US Federal Trade Commission
Page read. Checked 2026-09-17.
M4 / Publisher commercial page
Interesting Engineering advertising
Interesting Engineering
Page read. Checked 2026-09-17.
Reference for publisher presentation/inventory; self-reported audience metrics not used as verified benchmarks.
L1 / Official reuse guidance
PMC copyright notice
NIH / National Library of Medicine
Full official copyright notice read on September 17, 2026. Checked 2026-09-17.
Access does not grant reuse permission. Check each article and any separately licensed image; no third-party research images are included in this package.
H4 / Government science education
How do we hear?
NIH / NIDCD
Page read. Checked 2026-09-17.
D4 / Government patient education
Type 1 diabetes
NIH / NIDDK
Page read. Checked 2026-09-17.
Month-level review date; no publication day inferred.
C4 / Government patient education
Immunotherapy for cancer
NIH / National Cancer Institute
Page read. Checked 2026-09-17.
T3 / Primary preclinical research
Local application of Usag-1 siRNA can promote tooth regeneration in Runx2-deficient mice
Scientific Reports / study investigators
Publisher full article read. Checked 2026-09-17.
Mouse tissue/Runx2-deficient experimental context. siRNA experiment is not the same intervention as the clinical antibody program.
C5 / Peer-reviewed primary follow-up study
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
Sethna, Guasp, Reiche and colleagues / Nature
Publisher HTML abstract and clinical-results sections read. Checked 2026-09-17.
Extended follow-up of a small Phase I cohort; not an independent randomized efficacy trial. No figure data reanalysis performed.
C6 / Research institution conference report
MSK AACR 2026 Research Roundup: personalized RNA vaccines for pancreatic cancer
Memorial Sloan Kettering Cancer Center
Pancreatic-vaccine section of institutional report read. Checked 2026-09-17.
Institutional account of conference findings; the conference abstract and a corresponding full peer-reviewed 2026 paper were not inspected. Not independent confirmation.
S2 / Regulator decision and submitted 510(k) summary
ARC-EX System: K251821 decision and indications for use
US Food and Drug Administration
FDA clearance PDF read; indication page visually inspected. Checked 2026-09-17.
US prescription indication. Does not establish local stock, cost, reimbursement or individual suitability.
S3 / Regulator clinical-evidence assessment
ARC-EX: De Novo classification decision summary DEN240014
US Food and Drug Administration
FDA De Novo decision summary read; benefit-limitations page visually inspected. Checked 2026-09-17.
Original clinic-use assessment, not a new randomized study or the later home-use decision.
N101 / Research-institution protocol announcement
World’s first clinical trial of a tooth-regeneration treatment
Kitano Hospital
Primary-source page read. Checked 2026-09-17.
Historical trial plan, not completed Phase I results or current recruitment. Planned dates are not treated as completed milestones.
N102 / Government dental-science explanation
The Tooth Decay Process: How to Reverse It and Avoid a Cavity
National Institute of Dental and Craniofacial Research
Primary-source page read. Checked 2026-09-17.
Used for the distinction between early mineral loss and a formed cavity; not a whole-tooth-regeneration trial.
N103 / Government device information
Dental Implants: What You Should Know
U.S. Food and Drug Administration
Primary-source page read. Checked 2026-09-17.
General device information; not a head-to-head comparison with investigational tooth regrowth or a local cost estimate.
N104 / Government hearing-science explanation
Noise-Induced Hearing Loss
National Institute on Deafness and Other Communication Disorders
Primary-source page read. Checked 2026-09-17.
Not evidence that a new hair-cell-regeneration treatment has been approved.
N105 / Research-institution account of its study
Brain-computer interface enables independent, accurate communication for man living with ALS
UC Davis Health
Primary-source page read. Checked 2026-09-17.
Institutional account read; linked Nature Medicine paper could not be retrieved reliably. Participant-rated sentence correctness and controlled word accuracy are different measures.
N106 / Research-partner account
Brain-computer interface enables independent communication at home
U.S. Department of Veterans Affairs research
Indexed primary-source text accessed. Checked 2026-09-17.
Summary of the same UC Davis/Brown/BrainGate research, not a separate cohort or independent replication.
N107 / Peer-reviewed research paper
Simultaneous speech and gesture decoding for multimodal communication in paralysis
Nature Neuroscience / Brosler and colleagues
Publisher full text accessed; abstract, participant and task descriptions read. Checked 2026-09-17.
Three participants in isolated movement experiments; two in the simultaneous speech/gesture task. Restricted task vocabularies, not unrestricted everyday conversation.
N108 / Research-funder account
Brain-computer interface restores natural speech after paralysis
National Institutes of Health
Primary-source page read. Checked 2026-09-17.
Explains the 2025 streaming study. Computational time, speech latency and word accuracy must not be interchanged.
N109 / Professional-body public explanation
Augmentative and Alternative Communication (AAC)
American Speech-Language-Hearing Association / Helping You Communicate
ASHA public URL followed to current public education page. Checked 2026-09-17.
General communication-support information, not a clinical trial comparing AAC with implants.
N110 / Peer-reviewed research paper
Walking naturally after spinal cord injury using a brain–spine interface
Nature / Lorach and colleagues
Publisher text retrieved during this research pass; subsequent fetch was intermittent. Checked 2026-09-17.
Single-participant research demonstration. Does not establish a commercially available universal paralysis treatment.
N111 / Developer pipeline statement
Vertex Reports Second Quarter 2026 Financial Results
Vertex Pharmaceuticals
Primary-source page read. Checked 2026-09-17.
Current enrollment/dosing and program plans are developer statements, not independent clinical results or regulatory approval.
N112 / Developer program-discontinuation statement
Vertex Reports First Quarter 2025 Financial Results
Vertex Pharmaceuticals
Primary-source page read. Checked 2026-09-17.
Reports VX-264 did not meet the efficacy endpoint and was discontinued. Does not prove the mechanism of failure or failure of all encapsulation approaches.
N113 / Product approval record
LANTIDRA
U.S. Food and Drug Administration
Primary-source page read. Checked 2026-09-17.
U.S. approval and indication only; does not establish availability, coverage or price for a particular person.
N114 / Approved product labeling
LANTIDRA (donislecel-jujn) Prescribing Information
U.S. Food and Drug Administration
PDF read; indication and outcome/safety pages visually inspected. Checked 2026-09-17.
Small uncontrolled studies with repeated infusions in some participants. Duration subgroup formatting in the label is not used to construct new percentages.
N115 / Developer account of follow-up publication
Sana announces 14-month UP421 follow-up publication in NEJM
Sana Biotechnology
Primary-source page read. Checked 2026-09-17.
Company account read; underlying 2026 letter not independently accessed. Low-dose donor-islet proof of concept is not an SC451 clinical result or demonstrated insulin independence.
N116 / Developer pipeline statement
Sana Biotechnology Reports Second Quarter 2026 Financial Results
Sana Biotechnology
Primary-source page read. Checked 2026-09-17.
SC451 plans are forward-looking. No trial start, approval or completed future conference presentation is inferred.
N117 / Joint developer topline announcement
Merck and Moderna announce Phase 3 INTerpath-001 met recurrence-free and distant-metastasis-free survival endpoints
Merck and Moderna
Primary-source page read. Checked 2026-09-17.
Not a full Phase 3 paper. Phase 3 hazard ratios and absolute event rates are not supplied in the announcement. Phase 2b numbers in background paragraphs are not Phase 3 results.
N118 / Government treatment/research explanation
CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers
National Cancer Institute
Primary-source page read. Checked 2026-09-17.
Used to explain mechanism and risks, not an exhaustive current product-approval inventory.
N119 / Government treatment explanation
Immune Checkpoint Inhibitors
National Cancer Institute
Primary-source page read. Checked 2026-09-17.
General mechanism and adverse-effect context; not proof of benefit for an untested vaccine combination.
N120 / Official trial-search service
Find NCI-Supported Clinical Trials
National Cancer Institute
Official search landing page accessed; interactive search results not available in the parsed page. Checked 2026-09-17.
Not evidence of current recruitment, eligibility or complete trial coverage. Concrete trial listings are cited separately.
N121 / Product approval and indication record
PROVENGE (sipuleucel-T)
U.S. Food and Drug Administration
Primary-source page read. Checked 2026-09-17.
Indication-specific example, not a universal or preventive cancer vaccine.
N122 / Peer-reviewed research abstract
A streaming brain-to-voice neuroprosthesis to restore naturalistic communication
Nature Neuroscience / Littlejohn and colleagues; PubMed record
PubMed abstract read. Checked 2026-09-17.
Abstract access; additional performance details are attributed separately to NIH. One participant, not an efficacy rate for all people with speech loss.
N123 / Approved product labeling
OTARMENI Prescribing Information
U.S. Food and Drug Administration
PDF read; clinical-study population page visually inspected. Checked 2026-09-17.
Approval population and clinical evidence population differ. The 24-week endpoint is hearing sensitivity, not a guarantee of normal language development; procedures are not reproduced as self-treatment instructions.
N124 / Regulatory clinical assessment
Summary Basis for Regulatory Action — OTARMENI
U.S. Food and Drug Administration
PDF text read, including efficacy and extrapolation rationale. Checked 2026-09-17.
Primary benefit-risk interpretation for the initial U.S. authorization. Week-24 and week-48 denominators are distinct; no later cutoff is invented.
N125 / Current product record
OTARMENI product and indication record
U.S. Food and Drug Administration
Primary-source page read. Checked 2026-09-17.
U.S. indication, not an international approval or individual treatment-availability determination.
N126 / Peer-reviewed trial abstract
KEYNOTE-942: individualized mRNA-4157 plus pembrolizumab versus pembrolizumab, randomized Phase 2b study
The Lancet; author-affiliated UT Health San Antonio repository
Full abstract and bibliographic record read in an author-affiliated repository. Checked 2026-09-17.
Abstract-level access, not the full protocol or supplement. Initial analysis; not the later Phase 3 trial.
N127 / Peer-reviewed follow-up abstract
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
Nature; Weill Cornell Medicine author repository
Complete abstract and DOI record read. Checked 2026-09-17.
Same Phase 1 cohort as the 2023 report. Full Nature article was not reliably accessible in this pass; mechanistic claims are limited to the accessible abstract.
N128 / Official explanatory article
Can mRNA vaccines help treat cancer?
National Cancer Institute
Full article read. Checked 2026-09-17.
Used for biological/manufacturing concepts only. Its 2022 approval and trial-count statements are not treated as current 2026 status.
N129 / Government patient education
Who Pays for Clinical Trials?
NIH / National Cancer Institute
Official page read. Checked 2026-09-17.
US cancer-trial cost categories. Does not determine any individual insurance policy, sponsor budget or country rules.
N130 / Official trial listing
KEYNOTE-942 trial record, NCI-2019-04957 / NCT03897881
National Cancer Institute
Trial description, eligibility and status read on September 17, 2026. Checked 2026-09-17.
Listing stated closed to accrual. Status may subsequently change; no participant eligibility or site availability was confirmed.
N131 / Official trial listing
Personalized peptide vaccine for molecular residual disease, NCI-2025-00334
National Cancer Institute
Protocol summary, listed status and eligibility text read. Checked 2026-09-17.
Listing stated active on September 17, 2026; this is not a verified open slot or personal eligibility decision. Used to distinguish peptide from mRNA research.
N132 / Joint developer announcement
INTerpath-001 Phase 3 topline announcement, joint Merck/Moderna release
Merck and Moderna
Complete announcement read on Moderna newsroom; Merck copy also read earlier but later returned HTTP 403. Checked 2026-09-17.
Same announcement as N117, not independent corroboration. Phase 3 effect sizes and full tables were not supplied; numerical five-year results in its background concern Phase 2b.
N133 / Official consumer warning
Important patient and consumer information about regenerative medicine therapies
US Food and Drug Administration
Full warning read; historical publication date retained. Checked 2026-09-17.
Used for the warning that registration/listing is not marketing approval and that unproven products can cause harm. Its 2021 categorical inventory of approved therapies is not represented as a current 2026 inventory.
N134 / Developer approval and access announcement
Otarmeni FDA approval and U.S. no-cost product announcement
Regeneron
Complete manufacturer announcement read; eligibility and U.S. product-cost paragraph inspected. Checked 2026-09-17.
Manufacturer commits to supplying the product without charge to clinically eligible U.S. individuals. Administration costs can remain; no individual coverage, appointment capacity or total bill verified. Approval/effectiveness checked separately in FDA records.
M201 / Regulator approval summary
FDA Approves Drug for Pediatric Stage 3 Type I Diabetes
US Food and Drug Administration
Official page read. Checked 2026-09-17.
US indication and regulator summary. The underlying PROTECT paper was not independently accessed for this edition.
M202 / Product prescribing information
TZIELD prescribing information, revised June 2026
Sanofi / US prescribing information
PDF text read; indication and warning pages visually inspected. Checked 2026-09-17.
US label. Not a personal eligibility assessment, dosing guide, price quotation or insurance determination.
M203 / Government patient education
Artificial Pancreas
NIH / NIDDK
Official page read. Checked 2026-09-17.
General technology explanation, not a complete September 2026 device catalogue or head-to-head comparison.
M204 / Regulator announcement
FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-Refractory Acute Graft-Versus-Host Disease
US Food and Drug Administration
Official page read. Checked 2026-09-17.
Historical US approval. The indication does not extend to unrelated commercial stem-cell services.
M205 / Product prescribing information
RYONCIL prescribing information
US Food and Drug Administration / product labeling
PDF text read; clinical-study description and efficacy table visually inspected. Checked 2026-09-17.
Single-arm study; 55 enrolled, 54 treated. Day-28 overall response is not survival or a 70% cure rate.
M206 / Regulator product record
RYONCIL product record
US Food and Drug Administration
Official page read. Checked 2026-09-17.
US product/indication record, not worldwide access or price information.
M207 / Historical consumer alert
Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes
US Food and Drug Administration
Official page read. Checked 2026-09-17.
Historical alert. Its statement about the only approved stem-cell products is not used as a complete current inventory; later approvals exist.
M209 / Government coverage guidance
Clinical research studies coverage
US Centers for Medicare & Medicaid Services
Official page read. Checked 2026-09-17.
Coverage is conditional; no current deductible amount or individual coverage decision is asserted.
M210 / Government access guidance
Expanded Access
US Food and Drug Administration
Official page read. Checked 2026-09-17.
US expanded access, not worldwide compassionate-use rules or permission for a specific patient.
M211 / Government patient guidance
Expanded Access: Information for Patients
US Food and Drug Administration
Official page read. Checked 2026-09-17.
Manufacturer cooperation, clinical management and applicable reviews remain necessary. No access service is supplied by this publication.
M212 / Government patient education
Access to Experimental Cancer Drugs
NIH / National Cancer Institute
Official page read. Checked 2026-09-17.
US background guidance; no prediction of sponsor supply, trial eligibility, efficacy or coverage.
M213 / Government consumer guidance
Is It Really FDA Approved?
US Food and Drug Administration
Official page read. Checked 2026-09-17.
Explains category differences; no blanket clearance of an advertiser or medical business.
M214 / Regulator device-pathway guidance
Premarket Notification 510(k)
US Food and Drug Administration
Official page read. Checked 2026-09-17.
US pathway explanation. A specific device requires its own record and labeling.
M215 / Regulator device-pathway guidance
De Novo Classification Request
US Food and Drug Administration
Official page read. Checked 2026-09-17.
No-predicate low/moderate-risk device pathway, not an automatic ranking of clinical effectiveness.
M216 / Government science explanation
What Is Gene Therapy?
US Food and Drug Administration
Official page read. Checked 2026-09-17.
Mechanism categories only; does not establish current approval or availability for any unnamed therapy.
M217 / Government science explanation
What are genome editing and CRISPR-Cas9?
NIH / MedlinePlus Genetics
Official page read. Checked 2026-09-17.
Used for genome-editing mechanisms, not as a current approvals catalogue.
M218 / Regulator announcement
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
US Food and Drug Administration
Official page read. Checked 2026-09-17.
Historical Casgevy/Lyfgenia mechanism examples, not a comparative-effectiveness trial or complete current labeling review.
M219 / Primary institution research account
Clinical trials show encouraging safety profile for brain-computer interface turning thoughts into action
Brown University / BrainGate research team
Official page read. Checked 2026-09-17.
Institutional account of a 14-participant historical safety cohort. Underlying full Neurology paper was not independently accessed.
M220 / Final guidance
Implanted Brain-Computer Interface Devices: Non-clinical Testing and Clinical Considerations
US Food and Drug Administration
Guidance PDF text read for device/study-scope and follow-up considerations. Checked 2026-09-17.
Guidance is not approval of a particular BCI or evidence that risk has been eliminated.
M221 / Study-team information
BrainGate clinical trials
BrainGate research consortium
Official page read. Checked 2026-09-17.
Sponsor/team webpage, not a guarantee of a place, current availability at a named site or commercial sale.
H201 / Official patient information
Migraine
National Library of Medicine / MedlinePlus
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H202 / Official patient information
Migraine
NHS
HTML page reopened for the relevant revision; historical source dates and scope preserved. Checked 2026-09-18.
General health information; not individualized medical advice or a new trial report.
H203 / Official patient information
Migraine: MedlinePlus Genetics
National Library of Medicine / MedlinePlus Genetics
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H204 / Official patient information
10 common migraine triggers and how to cope with them
NIH MedlinePlus Magazine
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H205 / Official patient information
Treating Migraines: Ways to Fight the Pain with Medication
FDA
HTML page reopened for the relevant revision; historical source dates and scope preserved. Checked 2026-09-18.
General health information; not individualized medical advice or a new trial report.
H270 / Official patient information
Migraine: Diagnosis and treatment
Mayo Clinic
HTML page reopened for the relevant revision; historical source dates and scope preserved. Checked 2026-09-18.
General health information; not individualized medical advice or a new trial report.
H271 / Official patient information
Shingles (herpes zoster)
World Health Organization
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H207 / Official patient information
About Shingles (Herpes Zoster)
CDC
HTML page reopened for the relevant revision; historical source dates and scope preserved. Checked 2026-09-18.
General health information; not individualized medical advice or a new trial report.
H209 / Official clinical guidance
Clinical Overview of Shingles (Herpes Zoster)
CDC
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H210 / Official patient information
Shingles
NHS
HTML page reopened for the relevant revision; historical source dates and scope preserved. Checked 2026-09-18.
General health information; not individualized medical advice or a new trial report.
H211 / Official patient information
Shingles Vaccination
CDC
Accessible page text inspected. Checked 2026-09-17.
United States vaccine recommendations; not individualized advice or post-exposure treatment.
H208 / Official patient information
Shingles Symptoms and Complications
CDC
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H213 / Official patient information
About Impetigo
CDC
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H214 / Official clinical guidance
Clinical Guidance for Group A Streptococcal Impetigo
CDC
Accessible page text inspected. Checked 2026-09-17.
US clinical guidance. Return-to-school advice is jurisdiction-specific.
H216 / Official patient information
Staphylococcal infections
NHS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H215 / Official patient information
Impetigo
NHS
Accessible page text inspected. Checked 2026-09-17.
UK patient guidance; school exclusion guidance is identified as UK-specific.
H217 / Official patient information
Sciatica
NHS
HTML page reopened for the relevant revision; historical source dates and scope preserved. Checked 2026-09-18.
General health information; not individualized medical advice or a new trial report.
H218 / Official patient information
Sciatica: Medical Encyclopedia
A.D.A.M. medical encyclopedia hosted by MedlinePlus
Accessible page text inspected. Checked 2026-09-17.
Third-party medical encyclopedia hosted by NLM; not a government-authored research report. No images or source wording republished.
H219 / Official patient information
Slipped disc
NHS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H220 / Official patient information
Back pain
NHS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H221 / Official patient information
What Is Insomnia?
NIH / NHLBI
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H222 / Official patient information
Insomnia: Symptoms
NIH / NHLBI
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H225 / Official patient information
Insomnia: Diagnosis
NIH / NHLBI
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H223 / Official patient information
Insomnia: Causes and Risk Factors
NIH / NHLBI
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H226 / Official patient information
Insomnia
NHS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H224 / Official patient information
Insomnia: Treatment
NIH / NHLBI
HTML page reopened for the relevant revision; historical source dates and scope preserved. Checked 2026-09-18.
General health information; not individualized medical advice or a new trial report.
H269 / Official patient information
Taking Z-drugs for Insomnia? Know the Risks
FDA
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H227 / Official patient information
Psoriasis
NIH / NIAMS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H266 / Official patient information
Psoriasis
NHS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H228 / Official patient information
Psoriasis: Diagnosis, Treatment, and Steps to Take
NIH / NIAMS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H229 / Official patient information
Definition & Facts for Cirrhosis
NIH / NIDDK
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H230 / Official patient information
Symptoms & Causes of Cirrhosis
NIH / NIDDK
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H231 / Official patient information
Vitiligo
NIH / NIAMS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H267 / Official patient information
Vitiligo
NHS
Accessible page text inspected. Checked 2026-09-17.
Used for pattern, diagnostic differentiation and sun protection; not as an exhaustive current treatment list.
H275 / Official patient information
Vitiligo: Diagnosis and treatment
American Academy of Dermatology
Accessible page text inspected. Checked 2026-09-17.
Professional-society patient guidance. Page acknowledges Incyte support and states content was developed by AAD. Not a head-to-head trial or individualized recommendation.
H232 / Official patient information
Vitiligo: Diagnosis, Treatment, and Steps to Take
NIH / NIAMS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H233 / Manufacturer prescribing/safety information
Opzelura: US indications and important safety information
Incyte
Accessible page text inspected. Checked 2026-09-17.
US manufacturer page inspected for the named indication and warnings. Not an independent comparative-effectiveness source; no price or coverage inferred.
H234 / Official patient information
Alopecia Areata
NIH / NIAMS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H236 / Official patient information
Hair loss
NHS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H237 / Official patient information
Hair loss: Who gets and causes
American Academy of Dermatology
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H235 / Official patient information
Alopecia Areata: Diagnosis, Treatment, and Steps to Take
NIH / NIAMS
HTML page reopened for the relevant revision; historical source dates and scope preserved. Checked 2026-09-18.
General health information; not individualized medical advice or a new trial report.
H238 / Original-approval trial snapshot
Drug Trials Snapshots: LEQSELVI
FDA
HTML page reopened for the relevant revision; historical source dates and scope preserved. Checked 2026-09-18.
Original US approval evidence, not all subsequent labeling or a head-to-head comparison. Historical July 25, 2024 approval distinguished from current access.
H239 / Official patient information
What is dementia
NHS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H240 / Official patient information
Alzheimer's disease: Overview
NHS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H241 / Official patient information
Sudden confusion (delirium)
NHS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H243 / Official patient information
Dementia with Lewy bodies
NHS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H242 / Official patient information
Delirium
National Library of Medicine / MedlinePlus
Accessible page text inspected. Checked 2026-09-17.
Used for acute onset, attention changes and causes. Its oversimplified comparison of hallucinations is not repeated; NHS dementia/Lewy body information supplies that distinction.
H244 / Official patient information
Lymphoma
National Cancer Institute
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H245 / Patient evidence summary
Hodgkin Lymphoma Treatment (PDQ): Patient Version
National Cancer Institute
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H246 / Patient evidence summary
Non-Hodgkin Lymphoma Treatment (PDQ): Patient Version
National Cancer Institute
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H247 / Official patient information
Leukemia
National Cancer Institute
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H248 / Patient evidence summary
Acute Lymphoblastic Leukemia Treatment (PDQ): Patient Version
National Cancer Institute
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H249 / Patient evidence summary
Chronic Lymphocytic Leukemia Treatment (PDQ): Patient Version
National Cancer Institute
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H251 / Official patient information
Symptoms & Causes of Diarrhea
NIH / NIDDK
HTML page reopened for the relevant revision; historical source dates and scope preserved. Checked 2026-09-18.
General health information; not individualized medical advice or a new trial report.
H252 / Official patient information
Treatment of Diarrhea
NIH / NIDDK
HTML page reopened for the relevant revision; historical source dates and scope preserved. Checked 2026-09-18.
General health information; not individualized medical advice or a new trial report.
H255 / Official patient information
Diarrhoea and vomiting
NHS
Accessible page text inspected. Checked 2026-09-17.
UK service advice; urgent symptoms distinguished from local telephone and exclusion rules.
H253 / Official patient information
Eating, Diet, & Nutrition for Diarrhea
NIH / NIDDK
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H256 / Official patient information
About Norovirus
CDC
HTML page reopened for the relevant revision; historical source dates and scope preserved. Checked 2026-09-18.
General health information; not individualized medical advice or a new trial report.
H274 / Official patient information
Diarrhea
National Library of Medicine / MedlinePlus
Accessible page text inspected. Checked 2026-09-17.
Used for symptoms, causes and adult warning signs. Different food/drink suggestions across sources are not silently combined into a universal diet.
H250 / Official patient information
Definition & Facts for Diarrhea
NIH / NIDDK
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H254 / Official patient information
Diagnosis of Diarrhea
NIH / NIDDK
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H259 / Official patient information
Symptoms & Causes of Irritable Bowel Syndrome
NIH / NIDDK
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H257 / Official patient information
Constipation
NHS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H258 / Official patient information
Fecal impaction: Medical Encyclopedia
A.D.A.M. medical encyclopedia hosted by MedlinePlus
Accessible page text inspected. Checked 2026-09-17.
Third-party medical encyclopedia; general explanation of impaction, not instructions for self-disimpaction.
H262 / Official patient information
Types of Glaucoma
NIH / National Eye Institute
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H260 / Official patient information
Glaucoma
NIH / National Eye Institute
HTML page reopened for the relevant revision; historical source dates and scope preserved. Checked 2026-09-18.
General health information; not individualized medical advice or a new trial report.
H272 / Official patient information
Glaucoma and Eye Pressure
NIH / National Eye Institute
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H273 / Official patient information
Glaucoma Medicines
NIH / National Eye Institute
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H261 / Official patient information
Cataracts
NIH / National Eye Institute
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H268 / Official patient information
Cataract Surgery
NIH / National Eye Institute
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H263 / Official patient information
Menopause and perimenopause: Symptoms
NHS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H264 / Official patient information
Menopause basics
Office on Women's Health / HHS
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
H265 / Official patient information
About Primary Ovarian Insufficiency
NIH / NICHD
Accessible page text inspected. Checked 2026-09-17.
General health information; not individualized medical advice or a new trial report.
C301 / Official public guidance
Cataract surgery
Medicare.gov
HTML page read; no private account or personal assessment. Checked 2026-09-18.
US Original Medicare coverage and cost sharing. No personal benefit, quoted price or Advantage-plan determination.
C302 / Official public guidance
Eyeglasses & contact lenses
Medicare.gov
HTML page read; no private account or personal assessment. Checked 2026-09-18.
US coverage and supplier conditions; specific plan and individual bill not assessed.
C303 / Official public guidance
Mobile App: CBT-i Coach
US Department of Veterans Affairs / National Center for PTSD
HTML page read; no private account or personal assessment. Checked 2026-09-18.
Developer intended-use description and free availability; app not installed or clinically tested. Updated April 21, 2026.
C304 / Official public guidance
What is a good faith health insurance estimate?
Centers for Medicare & Medicaid Services
HTML page read; no private account or personal assessment. Checked 2026-09-18.
US guidance for not using insurance. Not a global price or legal determination; page modified August 25, 2026.
C305 / Official public guidance
Allowed amount
HealthCare.gov
HTML page read; no private account or personal assessment. Checked 2026-09-18.
US glossary definition, not actual allowance or personal coverage.
C306 / Official public guidance
Dispute a medical bill
Centers for Medicare & Medicaid Services
HTML page read; no private account or personal assessment. Checked 2026-09-18.
US patient-provider dispute eligibility and process, not a determination that a reader qualifies or will win.
C307 / Official public guidance
Appealing an insurance company decision
HealthCare.gov
HTML page read; no private account or personal assessment. Checked 2026-09-18.
General US coverage appeal pathways, not the specific plan denial or complete legal advice.
C308 / Official clinical or public-health information
Migraine: Symptoms and causes
Mayo Clinic
HTML page read. Checked 2026-09-18.
Clinical information published by the treating institution; used for attack stages and one- or two-sided pain, not as evidence that this publication matches its medical authority.
C309 / Official clinical or public-health information
How to Prevent Norovirus
Centers for Disease Control and Prevention
HTML page read. Checked 2026-09-18.
Used for soap-and-water advice and sanitizer limitations. Not proof of an individual infection or outbreak.
W401 / Official patient or clinical guidance
Tension headaches
NHS
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W402 / Official patient or clinical guidance
Sinus headaches: symptoms and causes
Mayo Clinic
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W403 / Clinical classification
ICHD-3: Medication-overuse headache
International Headache Society
Relevant HTML text inspected. Checked 2026-09-18.
Clinical criteria, including medication-specific expert-consensus thresholds; not safe-use limits or a self-diagnosis rule.
W404 / Official patient or clinical guidance
Medication-overuse headache: diagnosis and treatment
Mayo Clinic
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W405 / Official patient or clinical guidance
Atopic dermatitis
NIH / NIAMS
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W406 / Official patient or clinical guidance
Atopic dermatitis: diagnosis, treatment and steps to take
NIH / NIAMS
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W407 / Official patient or clinical guidance
Scalp psoriasis: treatment
American Academy of Dermatology
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W408 / Official patient or clinical guidance
Seborrheic dermatitis: overview
American Academy of Dermatology
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W409 / Official patient or clinical guidance
Do you have hair loss or hair shedding?
American Academy of Dermatology
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W410 / Official patient or clinical guidance
Telogen effluvium
British Association of Dermatologists
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W411 / Official patient or clinical guidance
Female pattern hair loss: a common, treatable condition
American Academy of Dermatology
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W412 / Official patient or clinical guidance
Sleep apnea: symptoms
NIH / NHLBI
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W413 / Official patient or clinical guidance
Sleep apnea: diagnosis
NIH / NHLBI
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W414 / Official patient or clinical guidance
Shingles vaccine recommendations
CDC
Relevant HTML text inspected. Checked 2026-09-18.
US clinical schedule guidance checked September 18, 2026; recommendations can change.
W415 / Official patient or clinical guidance
Shingles shots
Medicare.gov
Relevant HTML text inspected. Checked 2026-09-18.
US Medicare coverage guidance; not a statement about all insurance plans or a personal bill.
W416 / Official patient or clinical guidance
Preventive health services
HealthCare.gov
Relevant HTML text inspected. Checked 2026-09-18.
US coverage guidance; plan, network and service conditions matter.
W417 / Official patient or clinical guidance
OTC hearing aids: what you should know
FDA
Relevant HTML text inspected. Checked 2026-09-18.
US OTC device category and consumer guidance, not a product endorsement or individually assessed suitability.
W418 / Official patient or clinical guidance
Over-the-counter hearing aids
NIH / NIDCD
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W419 / Official patient or clinical guidance
Sudden deafness
NIH / NIDCD
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W420 / Official patient or clinical guidance
Hearing aids
Medicare.gov
Relevant HTML text inspected. Checked 2026-09-18.
US Original Medicare versus possible other-plan benefits; no personal coverage confirmation.
W421 / US Medicare national coverage determination
National Coverage Determination 50.3: Cochlear implantation
CMS
Relevant HTML text inspected. Checked 2026-09-18.
Coverage criteria, not a quoted price or a guarantee for a particular patient. Criteria effective September 26, 2022 distinguished from access date.
W422 / Official patient or clinical guidance
Benefits and risks of cochlear implants
FDA
Relevant HTML text inspected. Checked 2026-09-18.
General benefit/risk categories; device-specific labeling is needed for individual equipment restrictions. No blanket MRI rule is inferred.
W423 / Official patient or clinical guidance
Private cataract surgery: lens options
Moorfields Eye Hospital / Moorfields Private
Relevant HTML text inspected. Checked 2026-09-18.
Hospital/provider information used for monofocal, multifocal and toric distinctions. Not an independent comparison of every lens or commercial provider.
W424 / Official patient or clinical guidance
Cataract surgery
Guy’s and St Thomas’ NHS Foundation Trust
Relevant HTML text inspected. Checked 2026-09-18.
Hospital patient guidance; local pathways and postoperative instructions are not automatically transferable.
W425 / Official patient or clinical guidance
Get a dilated eye exam
NIH / National Eye Institute
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W426 / Official patient or clinical guidance
How is glaucoma diagnosed?
Glaucoma UK
Relevant HTML text inspected. Checked 2026-09-18.
UK charity guidance for common tests and referral; professional roles and access vary by country. No universal screening interval inferred.
W427 / Official patient or clinical guidance
Glaucoma
NHS
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W428 / Official patient or clinical guidance
Diabetes tests and diagnosis
NIH / NIDDK
Relevant HTML text inspected. Checked 2026-09-18.
General diagnostic thresholds for nonpregnant people; confirmation, clinical context and different pregnancy pathways matter.
W429 / Official patient or clinical guidance
The A1C test & diabetes
NIH / NIDDK
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W430 / Official patient or clinical guidance
Diabetic ketoacidosis
CDC
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W431 / Official patient or clinical guidance
Menopause: treatment
NHS
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W432 / Official patient or clinical guidance
Types of hormone replacement therapy
NHS
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W433 / Official patient or clinical guidance
Benefits and risks of hormone replacement therapy
NHS
Relevant HTML text inspected. Checked 2026-09-18.
General guidance with an older displayed review date; not a personalized risk estimate or comprehensive review of newer therapies.
W434 / Official patient or clinical guidance
Diagnosis of irritable bowel syndrome
NIH / NIDDK
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W435 / Official patient or clinical guidance
Diagnosis of celiac disease
NIH / NIDDK
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W436 / Official patient or clinical guidance
Biopsy
Lymphoma Action
Relevant HTML text inspected. Checked 2026-09-18.
UK charity patient guidance; exact sample adequacy, reporting times and diagnostic needs are case-specific.
W437 / Official patient or clinical guidance
Pathology reports
National Cancer Institute
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W438 / Official patient or clinical guidance
Generic drug facts
FDA
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W439 / Official patient or clinical guidance
Biosimilars basics for patients
FDA
Relevant HTML text inspected. Checked 2026-09-18.
Used for biosimilarity and interchangeability concepts, not as an exhaustive current indication or product list.
W440 / Official patient or clinical guidance
Drug plan rules
Medicare.gov
Relevant HTML text inspected. Checked 2026-09-18.
US Part D plan rules and exceptions, not a guarantee of approval or coverage in other markets.
W441 / Official patient or clinical guidance
Bridges
American Dental Association / MouthHealthy
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W442 / Official patient or clinical guidance
Dentures
American Dental Association / MouthHealthy
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W443 / Cancer terminology reference
Objective response rate
National Cancer Institute
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W444 / Cancer terminology reference
Progression-free survival
National Cancer Institute
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W445 / Cancer terminology reference
Overall survival
National Cancer Institute
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.
W446 / Cancer terminology reference
Disease-free survival
National Cancer Institute
Relevant HTML text inspected. Checked 2026-09-18.
General information, not individual medical advice; not a systematic evidence review.